A year of COVID-19 GWAS results from the GRASP portal reveals potential SARS-CoV-2

modifiers

Florian Thibord[1], Melissa V. Chan[1], Ming-Huei Chen[1], Andrew D. Johnson[1,*]

[1] Division of Intramural Research, Population Sciences Branch, Framingham, MA 01702

*corresponding author: johnsonad2@nhlbi.nih.gov

Abstract

11   Host genetic variants influence the susceptibility and severity of several infectious

12 diseases, and the discovery of novel genetic associations with Covid-19 phenotypes could help

13 developing new therapeutic strategies to reduce its burden.

14   Between May 2020 and February 2021, we used Covid-19 data released periodically by

15 UK Biobank and performed over 400 Genome-Wide Association Studies (GWAS) of Covid-19

16 susceptibility (N=15,738 cases), hospitalization (N=1,916), severe outcomes (N=935) and death

17 (N=828), stratified by ancestry and sex.

18   In coherence with previous studies, we observed 2 independent signals at the

chr3p21.31 locus (rs73062389-A, OR=1.22, P=7.64×10^{-14} and rs13092887-A, OR=1.73,

P=2.38×10^{-8}, in Europeans) modulating susceptibility and severity, respectively, and a signal

influencing susceptibility at the *ABO* locus (rs9411378-A, OR=1.10, P =7.36×10^{-10}, in Europeans),

which was more significant in men than in women (P=0.01). In addition, we detected 7 genome-

wide significant signals in the last data release analyzed (on February 24th 2021), of which 4

were associated with susceptibility (*SCRT2*, *LRMDA*, chr15q24.2, *MIR3681HG*), 2 with

hospitalization (*ANKS1A*, chr12p13.31) and 1 for severity (*ADGRE1*). Finally, we identified over

300 associations which increased in significance over time, and reached at least $P<10^{-5}$ in the

last data release analyzed. We replicated 2 of these signals in an independent dataset: a variant

downstream of *CCL3* (rs2011959) associated with severity in men, and a variant located in an

ATP5PO intron (rs12482569) associated with hospitalization.

These results, freely available on the GRASP portal, provide new insights on the host

genetic architecture of Covid-19 phenotypes.

Introduction

The severe acute respiratory syndrome – coronavirus 2 (SARS-CoV-2) is responsible for

the coronavirus disease 2019 (Covid-19) which affects individuals with variable severity, ranging

from asymptomatic patients to mild respiratory symptoms, hypercytokinemia, pneumonia,

thrombosis and even death.[1,2] Understanding the mechanisms leading to heterogeneous

symptoms and susceptibility is essential in order to develop efficient treatments and improve

patient care. Host genetic diversity has been shown to influence the effects of infection to

several viruses,[3] such as variations in *CCR5* [MIM: 601373] leading to HIV resistance[4] [MIM:

609423] or *IRF7* [MIM: 605047] deficiency affecting *Influenza* susceptibility [MIM: 614680].[5]

In order to discover human genetic determinants to Covid-19 susceptibility and severity,

several biobanks and research groups worldwide collaborated to perform Genome-Wide

Association Studies (GWAS) and meta-analyses of the GWAS. In June 2020, a study involving

1,980 Covid-19 infected patients with respiratory failure was the first to reveal genome-wide

significant (P < 5 × 10^{-8}) associations at the 3p21.31 locus, encompassing *SLC6A20* [MIM:

605616] and several chemokine receptors, and at the *ABO* [MIM: 110300] locus on

chromosome 9.[6] These 2 signals were later validated in independent analyses for both Covid-19

susceptibility and severity[7,8] while additional significant associations were observed at loci

involved in immune response or inflammation, such as *IFNAR2* [MIM: 602376], *DPP9* [MIM:

608258], *TYK2* [MIM: 176941], *CCHCR1* [MIM: 605310] and *OAS1* [MIM: 164350]. Notably,

these findings implicate common and uncommon variants, while studies trying to identify

associations of rare variants have been unsuccessful so far.[9] The largest effort is currently led by

the Covid-19 host genetics initiative (Covid-19hgi),[10] which completed meta-analyses of results

shared by 46 studies as of January 18th 2021, and plan to release new results as additional data

is made available. A major contributor to this group is the UK Biobank (UKB)[11] which

periodically releases the results of Covid-19 tests and related deaths, as well as health care data

for its nearly 500,000 consented participants, to approved researchers.

We created a public Covid-19 GWAS results portal

(https://grasp.nhlbi.nih.gov/Covid19GWASResults.aspx) in order to provide rapid deep

annotation for emerging genetics results and facilitate open access to the scientific community.

We contribute to this resource by performing GWAS on each Covid-19 data release from the UK

Biobank, including sex-specific, ancestry-specific, and trans-ethnic Covid-19 related GWAS,

along with a deep set of annotations for top variants (with P < 1 × 10^{-5}). For each release, up to

65 GWAS have been generated including Covid-19 susceptibility, Covid-19 hospitalization,

severe Covid-19 with respiratory failure, and Covid-19 death. Here we describe the results of

these GWAS, 434 in total as of February 24th 2021, and report the evolution of signals

associated with these Covid-19 phenotypes over the consecutive datasets released by UKB

since May 2020. The latter approach, tracking the evolution of genetic signatures iteratively in

UKB, suggests a valuable new analytic approach in genetic biobank studies where emerging

true signals may be identified before they reach genome-wide significance based on their

trajectories of significance.

Materials and Methods

UK Biobank data

Analyses are based on v.3 of the UKB imputed dataset,[12] which provide genomic data

for 487,320 participants from multiple ethnicities, including 459,250 of European ancestry

(EUR), 7,644 of African ancestry (AFR), 9,417 of South Asian ancestry (SAS) and 11,009 of other

ancestries (OTHERS). Participants were enrolled at ages ranging from 37 to 73 and are 51.16%

female. UKB started to release Covid-19 test results of its participants on March 15th 2020, and

periodically update this resource as new cases are reported. Furthermore, information about

Covid-19 related death was made available from June 2020, while inpatient data and primary

care data was first added during the summer of 2020 and are periodically updated. Details

regarding the definition and selection of cases with Covid-19 susceptibility, Covid-19

hospitalization, Covid-19 severity, and Covid-19 death are available in **Table S1.**

Phenotype definition

Depending on the Covid-19 phenotype analyzed (susceptibility, hospitalization, severity,

or death), up to 3 different subsets of participants were used as controls. For Covid-19

susceptibility, cases with positive test results were analyzed against either participants tested

with negative results (labelled Tested), or against all participants without a positive test

(labelled Population). For analyses of Covid-19 hospitalization, patients hospitalized due to

Covid-19 were tested against non-hospitalized participants with a positive test (Positive), or

non-hospitalized participants with a test (Tested), or against all non-hospitalized participants

(Population). For analyses of Covid-19 severity, patients requiring invasive respiratory support

or patients who died from complications were tested against non-severe participants with a

positive test (Positive), or non-severe participants with a test (Tested) or all non-severe

participants (Population). For analyses of Covid-19 death, patients with Covid-19 death were

tested against participants with a positive test (Positive), or participants with a test (Tested) or

against all participants (Population).

Analyses

Each GWAS was conducted with SAIGE v0.38,[13] which controls for population

stratification, relatedness and case-control imbalance, and adjusted for baseline age (at

enrollment), sex and 10 genetic principal components. For the results uploaded to the GRASP

portal, variants were filtered on imputation quality ($r^2 > 0.3$), minor allele count (MAC > 2), and

minor allele frequency (MAF > 0.0001). However, for the results presented in this manuscript,

we applied a more stringent filter, and considered only well-imputed variants ($r^2 > 0.8$) and

common variants (MAF > 0.01). After applying this filter, the lambda (genomic control factor)

ranged from 0.991 to 1.027 in all 65 analyses of the 02.24.21 data release (**Table S2**), indicating

no systematic inflation. For analyses prior to the June 18th 2020 release, we conducted analyses

on participants of European ancestry only, and started adding new analyses stratified by sex

and ancestry from June 18th 2020 onward. GWAS were stratified for EUR, AFR, SAS, and OTHERS

ancestries, and an additional trans-ancestry GWAS combining all participants (labelled ALL) as

well as GWAS combining non-European (nEUR) participants were performed.

Associations are either reported as odd ratios (OR) and 95% confidence intervals or as

beta coefficients (β) and associated standard errors (SE). Linkage disequilibrium (LD) was

estimated by squared correlation (r^2) using UKB EUR imputed data. To test 2 observed effects

are equal, we used the Z statistic: $Z = \dfrac{b_1 - b_2}{\sqrt{SEb_1^2 + SEb_2^2}}$, with b_1 and b_2 corresponding to the

observed effects and SEb_1 and SEb_2 the associated standard errors.

Annotation

For each analysis hosted on the portal, we provide comprehensive annotation for top

results ($P < 1 \times 10^{-5}$) using ANNOVAR[14] and the RESTful API service provided by CADD v1.6.[15] We

also retrieve known phenotype associations extracted from the GRASP[16] and EBI GWAS

catalogs,[17] and known eQTLs extracted from GTeX v8[18] and other eQTL resources compiled

from nearly 150 datasets (built upon the work of Zhang *et al*,[19] detailed in **Table S3**).

Replication

The 6 Covid-19hgi meta-analyses, release version 5, excluding the UKB and 23andMe

datasets, were used for our replication efforts and include results for Covid-19 susceptibility

(labelled C2), hospitalization (B2) and severity (A2). The 3 meta-analyses restricted to European

individuals (EUR) were used to replicate signals observed in our GWAS involving European UKB

participants, while the remaining 3 trans-ancestry meta-analyses (ALL) were used to replicate

signals observed either in our trans-ancestry GWAS or in non-European analyses. A signal was

defined as replicated if the effect direction was concordant in the GWAS and the Covid-19hgi

meta-analysis, and if the p-value in the meta-analysis was below 0.1, corresponding to a one-

sided test threshold of 0.05. In addition, the Bonferroni method was applied to correct for

multiple testing.

Data Availability

Permission was obtained to post UKB summary statistics under an approved application

(ID 28525). The association results are available on the portal, as well as annotated top results.

In addition to UKB summary statistics, results from other efforts are also hosted on the portal.

Authors of Covid-19 GWAS publications have been contacted to seek approval before hosting

the results of their analyses on the GRASP Covid-19 portal. Summary statistics at this time

include multiple releases of the Covid-19hgi group, severe hospitalization results from

Ellinghaus *et al*[6] and the GenOMICC study,[7] with all results are being re-annotated in the

common framework mentioned above.

Results

UK Biobank Covid-19 demographics

Using the latest UKB data release available at this point, analyzed on February 24th 2021,

we retrieved 47,413 participants with a Covid-19 diagnostic, of which 15,738 tested positive.

According to inpatient care data, 1,916 positive cases were hospitalized, while 935 patients

with severe Covid-19 diagnostic received respiratory support and/or died from complications

(**Table 1**). Since May 7th 2020, we analyzed 15 UKB data releases regarding Covid-19

susceptibility, 7 data releases concerning Covid-19 related deaths, and 4 data releases for both

Covid-19 related hospitalization and Covid-19 severity. Amongst Covid-19 positive participants,

we observed a global increase in the percentage of female cases, starting at 45.3% at the first

release analyzed, and reaching 52.47% in the last, while men were more likely to be infected (P

$= 9.94 \times 10^{-7}$), hospitalized (P $= 1.34 \times 10^{-39}$), or develop severe complications (P $= 3.40 \times 10^{-29}$)

and die from Covid-19 (P $< 10^{-300}$) in the 02.24.21 data release (**Table S4**). There was also a

decrease in the mean age of positive cases, ranging from 57.02 to 53.77, with a significant drop

after the 2020 summer (**Table 2**), with younger individuals more likely to be infected (P $< 10^{-300}$)

while increase in age was associated with hospitalization (P $= 1.23 \times 10^{-73}$), severity (P $= 1.41 \times$

10^{-93}) and death (P $= 3.40 < 10^{-300}$) (**Table S4**). Positive cases were mainly of European ancestry,

representing 85.5% of all Covid-19 positive participants in the first analysis and growing to

89.3% in the last. South Asian ancestry, African ancestry, and other ancestry represent 4.4%,

3.2% and 3.1% of positive cases, respectively, in this UKB data release. However, compared to

European participants, non-European participants were more likely to be infected ($P = 9.34 \times$

10^{-37} for AFR, $P = 6.68 \times 10^{-82}$ for SAS, $P = 4.31 \times 10^{-8}$ for OTHERS), hospitalized ($P = 2.78 \times 10^{-28}$

for AFR, $P = 2.23 \times 10^{-9}$ for SAS, $P = 1.01 \times 10^{-6}$ for OTHERS), severe ($P = 2.89 \times 10^{-19}$ for AFR, $P =$

9.84×10^{-4} for SAS, $P = 0.02$ for OTHERS) and deceased participants ($P = 2.72 \times 10^{-10}$ for AFR, $P =$

7.04×10^{-3} for SAS) (**Table S4**).

Associations with Covid-19 susceptibility

The genome-wide significant loci in the last data release analyzed (on 02.24.21) for

Covid-19 susceptibility are presented in **Table 3**, while all associations with $P < 10^5$ are available

in **Table S5**. In addition, all signals reaching genome-wide significance in any data release

analyzed are presented in **Figures S1-S18**.

This project started with the analysis of Covid-19 susceptibility in participants of

European ancestry, as the largest ancestry group in UKB. Consequently, it is the most repeated

analysis with 15 iterations. With untested or negatively tested participants as controls

(Population controls), 8 signals reached genome-wide significance ($P < 5 \times 10^{-8}$) at some point

(**Figure 1**), of which only 3 remained significant in the last data release analyzed: the chr3p21.31

locus encompassing *SLC6A20* and several chemokine receptors (rs73062389-A, MAF = 0.06, OR

= 1.22 [1.16; 1.29], $P = 7.64 \times 10^{-14}$), the *ABO* locus on chromosome 9 (rs9411378-A, MAF =

0.22, OR = 1.10 [1.07; 1.14], $P = 7.36 \times 10^{-10}$) and intronic variants located in *SCRT2* and *SRXN1*

[MIM: 617583] on chromosome 20 (rs749199237-del.G, MAF = 0.35, OR = 1.08 [1.05; 1.11], P =

1.29×10^{-8}). The chr3p21.31 and *ABO* loci were previously reported to modulate Covid-19

susceptibility,[6–8,10] while the third signal on chromosome 20 was novel.

Amongst the 5 other signals no longer significant in this data release, the *APOE* [MIM:

107741] variant tagging for the APOE-ε4 haplotype (rs429358-C, MAF = 0.15, OR = 1.38 [1.24;

1.53], P = 1.80 × 10^{-9}, on 07.14.20) was the only signal previously described,[20] and was notably

the first report of a genetic determinant for Covid-19 susceptibility. However, this previous

report was based on UKB data and this signal was not replicated in an independent dataset.

This association was greatly attenuated after the summer, when the number of Covid-19 cases

started to rise significantly and the mean age of infected participants decreased. The

interaction between age of participants and the *APOE* variant was significant (P = 3.4 × 10^{-6})

suggesting that a subset of older participant carriers of this variant was more at risk of Covid-19

infection. Remarkably, in the 02.24.21 data release, this variant is still suggestively associated

with Covid-19 severity (OR = 1.42 [1.24; 1.62], P = 4.36 × 10^{-7} in EUR) and death (OR = 1.45

[1.25; 1.67], P = 4.62 × 10^{-7} in EUR) suggesting a mechanism leading to lethal complications

after infection.

Using negatively tested participants as controls (Tested controls), the only signal

reaching genome-wide significance in this last data release was again the chr3p21.31 locus (P =

1.85 × 10^{-9}) with a different lead variant (rs73062394-T, MAF = 0.059, OR = 1.2 [1.13; 1.28]).

This variant was in moderate linkage disequilibrium (LD) with rs73062389 (r^2 = 0.59), which was

the second lead variant (P = 8.46 × 10^{-9}) for this analysis.

In other ancestry-stratified GWAS (AFR, SAS and OTHERS), no signal was found genome-

wide significant in the last data release analyzed. However, in the GWAS combining all non-

European participants, with Population controls, one signal was found significant at the *LRMDA*

[MIM: 614537] locus on chromosome 10 (rs114026383-C, MAF = 0.02, OR = 2.42 [1.78; 3.29], P

= 1.82 × 10^{-8}). According to gnomAD (v2.1.1),[21] this variant is mostly carried by individuals of

African ancestry (MAF = 0.04) and mainly absent in other ancestries. In the GWAS of African

ancestry participants, this signal is close to genome wide significance (P = 3.24 × 10^{-7}).

Interestingly, *LRMDA* variants have been found associated to lung function[22] [MIM: 608852]

and HIV viral load in an unadjusted GWAS,[23] but there was no evidence of LD between these

variants and rs114026383 (r^2 < 0.01).

Finally, in the trans-ancestry analyses combining all UKB participants, using the

Population controls, the signals at the chr3.p21.31 and *ABO* loci were also genome-wide

significant (rs73062389-A, P = 3.99 × 10^{-13} and rs9411378-A, P = 1.12 × 10^{-9}, respectively), and a

third signal was observed at the *MIR3681HG* locus on chromosome 2 (rs112938622-G, MAF =

0.22, OR = 1.08 [1.05; 1.12], P = 4.95 × 10^{-8}). When using Tested controls, only the chr3p21.31

signal was genome-wide significant in the last analysis (rs73062394-T, P = 1.99 × 10^{-8}).

In sex-stratified analyses, using Population controls, the chr3p21.31 signal was

significant in women (rs73062389-A, P = 1.06 × 10^{-8} in EUR and P = 1.35 × 10^{-8} in the trans-

ancestry GWAS) and highly associated in men (P = 1.12 × 10^{-6} in EUR and P = 3.19 × 10^{-6} in the

trans-ancestry GWAS), whereas the *ABO* signal was significant in men (rs9411378-A, P = 2.00 ×

10^{-8} in EUR and P = 2.05 × 10^{-8} in the trans-ancestry GWAS) and moderately associated in

women (P = 1.51 × 10^{-3} in EUR and P = 1.89 × 10^{-3} in the trans-ancestry GWAS). Notably, the

observed effect of the *ABO* signal was significantly stronger in men (β = 0.135, SE = 0.023 in

EUR) than in women (β = 0.068, SE = 0.021), using the Z-test for the equality of regression

coefficients (P = 0.015). In addition, when using Tested controls, an intergenic variant at the

chr15q24.2 locus was significant in the trans-ancestry GWAS of women (rs71401691-G, MAF =

0.07, OR = 1.23 [1.14; 1.32], P = 4.72×10^{-8}), but not in men (P = 0.89). According to GTeX, the

effect allele increases the transcription levels of *MAN2C1* (Mannosidase Alpha Class 2C Member

1, [MIM: 154580]) in several tissues including lungs (P = 6.7×10^{-14}) and esophagus-mucosa (P =

3.4×10^{-10}).

246   Several signals were genome-wide significant in analyses using a specific set of controls,

but were below the significance threshold when using another one. Notably, the *LRMDA* signal

had a stronger effect in the Population analysis (β = 0.88, SE = 0.16) than in the Tested analysis

(β = 0.62, SE = 0.16) and the intergenic variant at the chr15q24.2 locus had a stronger effect in

the Tested analysis (β = 0.20, SE = 0.04) than in the Population analysis (β = 0.13, SE = 0.03), as

represented in **Figure S19**. However, the difference in effects when using 2 different set of

controls was not significant when applying the Z-test for the equality of regression coefficients

(P > 0.05).

Associations with Covid-19 hospitalization, severity, and death

256   The genome-wide significant findings for Covid-19 hospitalization, severity and death

257   are presented in **Table 4**, while all associations with P < 10^{-5} are available in **Table S6**. Similarly

258   to the susceptibility analyses, all signals reaching genome-wide significance in any analysis are

259   presented in **Figures S20-S42**. Across all analyses of hospitalization and severity, we identified 4

260   loci reaching genome-wide significance in the last data release analyzed, while no significant

261   signal was observed in the GWAS of Covid-19 related death.

262   The most recurring signal is again located at the known chr3p21.31 locus. Depending on

the analysis, we observed 3 distinct leads variants at this locus: rs13071258 in the GWAS of

hospitalized Europeans, rs72893671 in the trans-ancestry hospitalization GWAS, and

rs13092887 in the severe Covid-19 GWAS of both Europeans and all ancestries. However, all 3

variants were in LD ($r^2 > 0.84$), suggesting a single haplotype modulating Covid-19

hospitalization and severity. As previously reported,[8] this haplotype seems distinct from the

signal of Covid-19 susceptibility (**Figure S43**), as the 2 susceptibility variants (rs73062389 and

rs73062394) are not in LD ($r^2 < 0.01$) with the 3 severity variants.

The 3 remaining signals were not previously reported, and were identified in sex-

stratified analyses. First, intronic variants in *ANKS1A* [MIM: 608994] were observed significantly

associated in several analyses of men with Covid-19-related hospitalization, for instance in EUR

using non-hospitalized participants with a positive test as controls (rs112887370-T, MAF = 0.02,

OR = 3.30 [2.18; 5.00], P = 1.71×10^{-8}). According to GTeX, this allele increases the transcript

levels of the nearby gene *C6orf106* [MIM: 612217] in some tissues (thyroid, P = 1.5×10^{-7} and

testis, P = 1.7×10^{-6}), while other alleles in LD also reaching genome-wide significance (e.g.

rs2504165-T, OR = 2.84 [1.96; 4.12], P = 3.99×10^{-8}, r^2 = 0.73) can decrease the transcript levels

of *C6orf106* in skeletal muscles (P = 3.2×10^{-5}). *C6orf106* is also known as *ILRUN* (Inflammation

and Lipid Regulator with UBA-like and NBR-1-like domains), a gene involved in the regulation of

antiviral response. Second, an intergenic indel located at the chr12p13.31 locus, between

CD163 [MIM: 605545] and *APOBEC1* [MIM: 600130], was associated with the hospitalization of

women when using non-hospitalized participants with a positive test (rs370732090-ins.ATTAT,

MAF = 0.14, OR = 0.61 [0.52; 0.73], P = 3.37×10^{-8}). Finally, an intronic insertion-deletion

located in *ADGRE1* [MIM: 600493] was associated with Covid-19 severity in European women,

using participants without severe Covid-19 as controls (rs770180814-ins.GT, MAF = 0.22, OR =

1.78 [1.45; 2.19], P = 4.51×10^{-8}).

Replication of novel genome-wide significant signals

The 7 novel signals identified were further investigated using the Covid-19hgi meta-

analyses results, where the UKB was not included. Unfortunately, variants constituting the

LRMDA and *APOBEC1* signals were absent from the meta-analyses, which prevented our effort

to replicate these 2 signals. Out of the 5 remaining signals, 4 did not reach nominal significance

in the replication datasets: at the *SCRT2* locus (rs749199237, P = 0.97 in C2 EUR), at the

MIR3681HG locus (rs112938622, P = 0.27 in C2 ALL), at the chr15q24.2 locus (rs71401691, P =

0.82 in C2 ALL) and at the *ADGRE1* locus (rs770180814, P = 0.55 in A2 EUR). Finally, at the

ANKS1A locus, the lead variant identified in the analysis of hospitalized Europeans men did not

replicate (rs112887370, P = 0.14 in B2 EUR) but another variant in LD mentioned earlier was

associated at nominal significance (rs2504165-T, OR = 1.13 [1.00; 1.28], P = 0.04 in B2 EUR).

Unfortunately, this association does not survive multiple-testing correction, with a threshold for

significance set at P < 0.017 for 6 one-sided tests. However, the *ANKS1A*, *ADGRE1* and

chr15q24.2 signals were identified in sex-stratified analyses, and the possibility for replication in

an independent sex-stratified dataset is not yet provided by Covid-19hgi.

Signals with suggestive significance trends

The significance trajectory of the most robust signals, at the chr3p21.31 and *ABO* loci,

mostly increased after the surge of new cases following the 09.08.20 data release (**Figure 1**).

After this date, the chr3p21.31 signal increased at each of the following 8 data release and

reached genome-wide significance in the 11.03.20 release, while the ABO signal increased 5

times out of 8 and reached significance in the 01.04.21 release. In order to identify signals that

may become significant in future releases, we extracted variants displaying similar positive

trends in significance, meaning variants not yet genome-wide significant, but exhibiting an

increase in significance since the 09.08.20 data release.

For each Covid-19 susceptibility GWAS, we extracted variants which had an increase in

significance in at least 6 out of the 8 releases following the 09.08.20 data release, and reached

$P < 10^{-5}$ in the last data release. For other Covid-19 phenotypes, considering that fewer data

releases were available, we extracted variants which increased in significance in all consecutive

releases, reaching the same significance threshold of $P < 10^{-5}$ in the last data release. After

excluding genome-wide significant signals, 2,409 variants involved in 3,607 associations variants

with suggestive trends were identified across all GWAS (**Table S7**).

Next, we sought to identify whether these signals with suggestive trends reached at

least nominal significance ($P < 0.05$) in the Covid-19hgi meta-analyses. Only signals from the

European and trans-ancestry GWAS were considered at this step, to match the corresponding

Covid-19hgi meta-analyses. Signals with suggestive trends from Covid-19 susceptibility GWAS

were sought for replication in the corresponding C2 (susceptibility) meta-analyses, while signals

with trends from the hospitalization and severe Covid-19 GWAS were sought for replication in

the B2 and A2 meta-analyses, respectively. In order to decrease the multiple-testing correction

burden, we only extracted the lead variant at each locus, a locus being defined as a genomic

region containing one or several variants with $P < 10^{-5}$ separated by less than 1Mb. As a result,

329 lead variants involved in 378 associations were extracted (**Table S8**), of which 18 had

concordant effects and reached nominal significance in the Covid-19-hgi meta-analyses (**Table**

5). After applying the multiple-testing Bonferroni correction, with one-sided hypothesis, only 2

signals passed the corrected significance threshold ($0.05*2/378 = 2.65 \times 10^{-4}$), both in trans-

ancestry analyses. The first signal had a positive significance trajectory in the hospitalization

GWAS (**Figure S44**) and is located 5Kb upstream of *ATP5PO* [MIM: 600828], encoding a part of

the ATP synthase complex. According to GTeX, the effect allele (rs12482569-A, MAF = 0.17, OR

= 1.22 [1.12; 1.33], $P = 6.28 \times 10^{-6}$) increases the transcript levels of *ATP5PO* in several tissues

including the lungs ($P = 4.6 \times 10^{-18}$) and the esophagus-mucosa ($P = 1.9 \times 10^{-11}$). The second

signal (rs2011959-A, MAF = 0.37, OR = 1.34 [1.18; 1.53], $P = 6.50 \times 10^{-6}$) had a positive trend in

the GWAS of men with severe Covid-19 (**Figure S45**), and is located 200 bp downstream of *CCL3*

[MIM: 182283], a pro-inflammatory cytokine, reported by numerous studies to have unusually

high levels in patients with severe Covid-19.[24–26]

Discussion and conclusions

This project was initiated with the major aim to share results of Covid-19 host genetics

analyses freely and rapidly on the GRASP portal, during a pandemic where new insights to

improve patient care and develop better treatments were greatly needed. A few months after

the first Covid-19 case was identified in the UK, we started to perform GWAS on each dataset

released by UKB between May 2020 and February 2021, and thus far examined genetic signals

associated with Covid-19 phenotypes across 15 data releases. This unique context allowed us to

track the evolution of genetic associations over time, an approach rarely applied. While some

works have examined the statistical properties of phased and nested case-control studies,[27,28]

few studies have proposed using statistical trajectories over time in genetic analyses.

As a first major observation, the majority of signals which were observed in the first

stages of the project did not sustain over time. For instance, the first genome-wide significant

association observed in the GWAS of Covid-19 susceptibility in Europeans with rs34338189 as

lead variant is not even nominally significant in the last release (P = 0.29). Another genome-

wide significant signal was observed at the *APOE* locus, with a significance that increased in the

first 4 data releases before decreasing continually in the subsequent releases. The lead variant

at the *APOE* locus is coding in part for the APOE-ε4 haplotype, known to increase the risk of

Alzheimer's disease [MIM: 607822], dementia, dyslipidemia and cardiovascular diseases [MIM:

617347] and is speculated to cause inflammation and cytokine storms.[29] Notably, the

suggestive association of the *APOE* signal with severe Covid-19 could support this proposition.

The evolution of the *APOE* signal over time could also be due to an initial higher prevalence of

Covid-19 in nursing homes,[30] where dementia patients were at higher risk of being infected and

spreading the virus due to living arrangements, and a poor understanding of transmission

dynamics and appropriate safety guidelines early in the pandemic. Overall, the evolution of

these signals suggests a change in the composition of cases over time, such as the diminution of

age and increase of positively tested women in the later data releases, as well as the

introduction of variant SARS-CoV2 strains. This change was most significant after the summer

when a surge in new Covid-19 infections occurred.

The most robust findings from our study are the association of the chr3p21.31 and *ABO*

loci with Covid-19 susceptibility and a distinct signal at the chr3p21.31 locus associated with

Hospitalization and severe Covid-19. These observations corroborate several previous reports,[6–

8,10] although we also observed a significant difference in the effect of the *ABO* variant between

men and women. Sex-stratified analyses also allowed us to identify a novel association between

ANKS1A variants and hospitalization of men, which reached nominal significance in the Covid-

19hgi hospitalization meta-analysis. Interestingly, the variants comprising this signal can also

influence the expression of *ILRUN*, either as an upregulator or as a repressor, depending on the

tissue. This gene is involved in innate immunity and has been recently shown to act as an

antiviral factor in the context of SARS-CoV-2 infection, notably by downregulating the

expression of *ACE2* [MIM: 300335] and *TMPRSS2* [MIM: 602060], the main SARS-CoV-2 entry

receptors.[31] This role differs from a previous report demonstrating an antiviral effect in cells

infected with Hendra virus,[32] which could hint at diverse roles for this gene in the context of

viral infection.

We have developed an original strategy to identify associations displaying increased

significance over time, and identified hundreds of loci with a significance trajectory suggesting

potential future genome-wide significance. Amongst these signals, 2 of them replicated at

nominal p-value in the Covid-19hgi meta-analyses, including a variant downstream of *CCL3*

suggestively associated with Severe Covid-19 in women, a cytokine with a well established high

expression in severe Covid-19 cases.[24–26] The associations we observed changing through the

pandemic could reflect random effects or changes in statistical power, but some of the results

suggest changes due to potential gene-environment interactions such as age, underlying health

conditions (*APOE*) or sex makeup of cases exposed to or engaging in risk behavior. This

indicates the general approach of iterative analysis and trends analyses for genetics during

pandemics may have benefits in uncovering pathophysiologic clues. Additionally, other factors

like predominant virus strains and changing treatment strategies through a pandemic might

interact with host genetics, and be better understood by iterative analyses.

In summary, our host genomic analyses of Covid-19 have improved the comprehension

of mechanisms involved in the infection and complications due to Covid-19 and we continue to

perform and rapidly share these analyses with the research community. Our study has some

limitations. Most importantly, our data and the work of others support large health disparities

between EUR and non-EUR individuals related to COVID-19 throughout the ongoing pandemic.

Despite an over-representation proportionally among cases and those with severe and fatal

outcomes, the non-EUR component of UKB is a proportionally small sample limiting our

statistical power to address population-specific genetic variants contributing to health

outcomes. Moving forward we feel that having a diverse set of results with different phenotype

definitions, sex-specific, ancestry-specific, and including external group summary statistics, all in

a common genome reference and annotation framework may maximize the chance for new

studies to cross-replicate or meta-analyze results as Covid-19 genetic studies continue to grow.

Description of Supplemental Data

Supplemental Data include 45 figures and 8 tables.

Declaration of Interests

The authors declare no competing interests.

Acknowledgments

All authors were supported by NIH Intramural Research Program funds. The views expressed in

this manuscript are those of the authors and do not necessarily represent the views of the

National Heart, Lung, and Blood Institute; the National Institutes of Health; or the U.S.

Department of Health and Human Services. This research has been conducted using the UK

Biobank Resource under Application Number 28525. UK Biobank was established by the

Wellcome Trust, Medical Research Council, Department of Health, Scottish government, and

Northwest Regional Development Agency. It has also had funding from the Welsh assembly

government and the British Heart Foundation. All UKB analyses for this manuscript were

conducted on the NIH Biowulf high performance computing cluster (https://hpc.nih.gov/). The

Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office

of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and

NINDS. We also thank the NHLBI IT team for their help in keeping the GRASP portal up to date.

Web Resources

GTeX : https://gtexportal.org/home/

CADD : https://cadd.gs.washington.edu/

EBI GWAS catalog : https://www.ebi.ac.uk/gwas/

GRASP catalog : https://grasp.nhlbi.nih.gov/Overview.aspx

Covid-19hgi meta-analyses results : https://www.covid19hg.org/results/r5/

GnomAD : https://gnomad.broadinstitute.org/

Data and Code Availability

The datasets generated during this study are available at the GRASP Covid-19 portal:

https://grasp.nhlbi.nih.gov/Covid19GWASResults.aspx

References

1. Connors, J.M., and Levy, J.H. (2020). COVID-19 and its implications for thrombosis and
anticoagulation. Blood *135*, 2033–2040.

2. Tang, D., Comish, P., and Kang, R. (2020). The hallmarks of COVID-19 disease. PLoS Pathog.
16, e1008536.

3. Kwok, A.J., Mentzer, A., and Knight, J.C. (2021). Host genetics and infectious disease: new
tools, insights and translational opportunities. Nat. Rev. Genet. *22*, 137–153.

4. Dragic, T., Litwin, V., Allaway, G.P., Martin, S.R., Huang, Y., Nagashima, K.A., Cayanan, C.,
Maddon, P.J., Koup, R.A., Moore, J.P., et al. (1996). HIV-1 entry into CD4+ cells is mediated by
the chemokine receptor CC-CKR-5. Nature *381*, 667–673.

5. Ciancanelli, M.J., Huang, S.X.L., Luthra, P., Garner, H., Itan, Y., Volpi, S., Lafaille, F.G., Trouillet,
C., Schmolke, M., Albrecht, R.A., et al. (2015). Life-threatening influenza and impaired
interferon amplification in human IRF7 deficiency. Science *348*, 448–453.

6. Ellinghaus, D., Degenhardt, F., Bujanda, L., Buti, M., Albillos, A., Invernizzi, P., Fernández, J.,
Prati, D., Baselli, G., Asselta, R., et al. (2020). Genomewide Association Study of Severe Covid-19
with Respiratory Failure. N. Engl. J. Med. *0*, null.

7. Pairo-Castineira, E., Clohisey, S., Klaric, L., Bretherick, A.D., Rawlik, K., Pasko, D., Walker, S.,
Parkinson, N., Fourman, M.H., Russell, C.D., et al. (2020). Genetic mechanisms of critical illness
in Covid-19. Nature 1–1.

8. Shelton, J.F., Shastri, A.J., Ye, C., Weldon, C.H., Filshtein-Sonmez, T., Coker, D., Symons, A.,
Esparza-Gordillo, J., Aslibekyan, S., and Auton, A. (2021). Trans-ancestry analysis reveals genetic
and nongenetic associations with COVID-19 susceptibility and severity. Nat. Genet. 1–8.

9. Kosmicki, J.A., Horowitz, J.E., Banerjee, N., Lanche, R., Marcketta, A., Maxwell, E., Bai, X., Sun,
D., Backman, J.D., Sharma, D., et al. (2021). Pan-ancestry exome-wide association analyses of
COVID-19 outcomes in 586,157 individuals. Am. J. Hum. Genet. *0*,.

10. Initiative, T.C.-19 H.G., and Ganna, A. (2021). Mapping the human genetic architecture of
COVID-19 by worldwide meta-analysis. MedRxiv 2021.03.10.21252820.

11. Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P.,
Green, J., Landray, M., et al. (2015). UK Biobank: An Open Access Resource for Identifying the
Causes of a Wide Range of Complex Diseases of Middle and Old Age. PLOS Med. *12*, e1001779.

12. Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L.T., Sharp, K., Motyer, A., Vukcevic,
D., Delaneau, O., O'Connell, J., et al. (2018). The UK Biobank resource with deep phenotyping
and genomic data. Nature *562*, 203–209.

13. Zhou, W., Nielsen, J.B., Fritsche, L.G., Dey, R., Gabrielsen, M.E., Wolford, B.N., LeFaive, J.,
VandeHaar, P., Gagliano, S.A., Gifford, A., et al. (2018). Efficiently controlling for case-control
imbalance and sample relatedness in large-scale genetic association studies. Nat. Genet. *50*,
1335–1341.

14. Wang, K., Li, M., and Hakonarson, H. (2010). ANNOVAR: functional annotation of genetic
variants from high-throughput sequencing data. Nucleic Acids Res. *38*, e164–e164.

15. Rentzsch, P., Witten, D., Cooper, G.M., Shendure, J., and Kircher, M. (2019). CADD:
predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res.
47, D886–D894.

16. Eicher, J.D., Landowski, C., Stackhouse, B., Sloan, A., Chen, W., Jensen, N., Lien, J.-P., Leslie,
R., and Johnson, A.D. (2015). GRASP v2.0: an update on the Genome-Wide Repository of
Associations between SNPs and phenotypes. Nucleic Acids Res. *43*, D799-804.

17. Buniello, A., MacArthur, J.A.L., Cerezo, M., Harris, L.W., Hayhurst, J., Malangone, C.,
McMahon, A., Morales, J., Mountjoy, E., Sollis, E., et al. (2019). The NHGRI-EBI GWAS Catalog of
published genome-wide association studies, targeted arrays and summary statistics 2019.
Nucleic Acids Res. *47*, D1005–D1012.

18. Aguet, F., Brown, A.A., Castel, S.E., Davis, J.R., He, Y., Jo, B., Mohammadi, P., Park, Y.,
Parsana, P., Segrè, A.V., et al. (2017). Genetic effects on gene expression across human tissues.
Nature *550*, 204–213.

19. Zhang, X., Gierman, H.J., Levy, D., Plump, A., Dobrin, R., Goring, H.H.H., Curran, J.E.,
Johnson, M.P., Blangero, J., Kim, S.K., et al. (2014). Synthesis of 53 tissue and cell line
expression QTL datasets reveals master eQTLs. BMC Genomics *15*, 532.

20. Kuo, C.-L., Pilling, L.C., Atkins, J.L., Masoli, J.A.H., Delgado, J., Kuchel, G.A., and Melzer, D.
(2020). ApoE e4e4 Genotype and Mortality With COVID-19 in UK Biobank. J. Gerontol. A. Biol.
Sci. Med. Sci. *75*, 1801–1803.

21. Karczewski, K.J., Francioli, L.C., Tiao, G., Cummings, B.B., Alföldi, J., Wang, Q., Collins, R.L.,
Laricchia, K.M., Ganna, A., Birnbaum, D.P., et al. (2020). The mutational constraint spectrum
quantified from variation in 141,456 humans. Nature *581*, 434–443.

22. Soler Artigas, M., Loth, D.W., Wain, L.V., Gharib, S.A., Obeidat, M., Tang, W., Zhai, G., Zhao,
J.H., Smith, A.V., Huffman, J.E., et al. (2011). Genome-wide association and large-scale follow up
identifies 16 new loci influencing lung function. Nat. Genet. *43*, 1082–1090.

23. Ekenberg, C., Tang, M.-H., Zucco, A.G., Murray, D.D., MacPherson, C.R., Hu, X., Sherman,
B.T., Losso, M.H., Wood, R., Paredes, R., et al. (2019). Association Between Single-Nucleotide
Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in
Demographically Diverse, Antiretroviral Therapy-Naive Participants From the Strategic Timing of
AntiRetroviral Treatment Trial. J. Infect. Dis. *220*, 1325–1334.

24. Chua, R.L., Lukassen, S., Trump, S., Hennig, B.P., Wendisch, D., Pott, F., Debnath, O.,
Thürmann, L., Kurth, F., Völker, M.T., et al. (2020). COVID-19 severity correlates with airway
epithelium-immune cell interactions identified by single-cell analysis. Nat. Biotechnol. *38*, 970–
979.

25. Hue, S., Beldi-Ferchiou, A., Bendib, I., Surenaud, M., Fourati, S., Frapard, T., Rivoal, S.,
Razazi, K., Carteaux, G., Delfau-Larue, M.-H., et al. (2020). Uncontrolled Innate and Impaired
Adaptive Immune Responses in Patients with COVID-19 Acute Respiratory Distress Syndrome.
Am. J. Respir. Crit. Care Med. *202*, 1509–1519.

26. Trump, S., Lukassen, S., Anker, M.S., Chua, R.L., Liebig, J., Thürmann, L., Corman, V.M.,
Binder, M., Loske, J., Klasa, C., et al. (2020). Hypertension delays viral clearance and exacerbates
airway hyperinflammation in patients with COVID-19. Nat. Biotechnol.

27. Van der Tweel, I., and van Noord, P.A. (2000). Sequential analysis of matched dichotomous
data from prospective case-control studies. Stat. Med. *19*, 3449–3464.

28. Boessen, R., van der Baan, F., Groenwold, R., Egberts, A., Klungel, O., Grobbee, D., Knol, M.,
and Roes, K. (2013). Optimizing trial design in pharmacogenetics research: comparing a fixed
parallel group, group sequential, and adaptive selection design on sample size requirements.
Pharm. Stat. *12*, 366–374.

29. Numbers, K., and Brodaty, H. (2021). The effects of the COVID-19 pandemic on people with
dementia. Nat. Rev. Neurol. *17*, 69–70.

30. Chen, M.K., Chevalier, J.A., and Long, E.F. (2021). Nursing home staff networks and COVID-
19. Proc. Natl. Acad. Sci. U. S. A. *118*,.

31. Tribolet, L., Alexander, M.R., Brice, A.M., van Vuren, P.J., Rootes, C.L., Mara, K., McDonald,
M., Bruce, K.L., Gough, T.J., Shi, S., et al. (2021). ILRUN downregulates ACE2 expression and
blocks infection of human cells by SARS-CoV-2. J. Virol.

32. Deffrasnes, C., Marsh, G.A., Foo, C.H., Rootes, C.L., Gould, C.M., Grusovin, J., Monaghan, P.,
Lo, M.K., Tompkins, S.M., Adams, T.E., et al. (2016). Genome-wide siRNA Screening at Biosafety
Level 4 Reveals a Crucial Role for Fibrillarin in Henipavirus Infection. PLoS Pathog. *12*, e1005478.

Figure Titles and Legends

Figure 1. Evolution of significant signals associated with covid-19 susceptibility in UKB

participants of European ancestry, using Population as controls.

The top panel represents the evolution in significance of signals reaching genome wide significance at least

once across all data releases analyzed in Europeans for Covid-19 susceptibility. The middle panel represent

the mean age of cases in each data release. The bottom panel represent the number of cases in each data

release.

Tables

Table 1. Sample sizes for each analysis, as of 02.24.21

Phenotype	Controls	Ancestry	Sex-stratified	Cases	Controls	Female Cases	Female Controls
Susceptibility	Test negative OR not tested (Population)	ALL	yes	15,738	471,582	8,258	255,971
		EUR	yes	14,054	445,196	7,396	241,903
		AFR		496	7,148	277	4,082
		SAS		693	8,724	300	4,031
		OTHERS		495	10,514	285	5,955
		nEUR		1,684	26,386	862	14,068
	Test negative (Tested)	ALL	yes	15,738	47,413	8,258	25,373
		EUR	yes	14,054	44,646	7,396	23,847
		AFR		496	809	277	501
		SAS		693	938	300	430
		OTHERS		495	1,020	285	595
		nEUR		1,684	2,767	862	1,526
Hospitalization	Not hospitalized (Population)	ALL	yes	1,916	485,404	735	263,494
		EUR	yes	1,712	457,538	655	248,644
		nEUR		204	27,866	80	14,850
	Tested, not hospitalized (Tested)	ALL	yes	1,916	61,235	735	32,896
		EUR	yes	1,712	56,988	655	30,588
		nEUR		204	4,247	80	2,308
	Test positive, not hospitalized (Positive)	ALL	yes	1,916	13,822	735	7,523
		EUR	yes	1,712	12,342	655	6,741
		nEUR		204	1,480	80	782
Severe Covid-19	Not severe (Population)	ALL	yes	935	486,385	320	263,909
		EUR	yes	848	458,402	283	249,016
	Tested, not severe (Tested)	ALL	yes	935	62,216	320	33,311
		EUR	yes	848	57,852	283	30,960
	Test positive, not severe (Positive)	ALL	yes	935	14,803	320	7,938
		EUR	yes	848	13,206	283	7,113
Death	Survivor (Population)	ALL		828	486,492	287	263,942
		EUR		758	458,492	258	249,041
	Tested, survivor (Tested)	ALL		828	62,323	287	33,344
		EUR		758	57,942	258	30,985
	Test positive, survivor (Positive)	ALL		828	14,910	287	7,971
		EUR		758	13,296	258	7,138

592 **Table 2**. Composition of the consecutive UK Biobank Covid-19 data releases
593

Release Date	Cases (tested positive)	Controls	% Tested Positive Females	Age Cases[a]
05.07.20[b]	1,029	486,291	45.29	57.02 (9.12)
05.25.20[b]	1,270	486,050	46.93	56.57 (9.25)
06.05.20	1,412	485,908	47.31	56.45 (9.23)
06.18.20	1,485	485,835	47.21	56.47 (9.19)
07.14.20	1,670	485,650	46.59	56.89 (9.14)
08.04.20	1,723	485,597	46.66	56.77 (9.11)
09.08.20	1,821	485,499	46.73	56.66 (9.10)
10.16.20	3,050	484,270	48.69	55.19 (9.09)
11.03.20	4,372	482,948	49.38	54.79 (8.95)
11.25.20	5,868	481,452	49.52	54.56 (8.88)
12.04.20	7,435	479,885	50.46	54.36 (8.80)
01.04.21	8,722	478,598	50.50	54.28 (8.79)
01.22.21	13,401	473,919	52.27	53.85 (8.66)
02.02.21	14,802	472,518	52.44	53.81 (8.64)
02.24.21	15,738	471,582	52.47	53.77 (8.63)

594
595 [a] Mean baseline Age (standard deviation), at recruitment
596 [b] For the first 2 releases, the numbers reflect all ancestries, but only cases and controls of European ancestry were
597 considered for analyses
598
599
600

615 **Table 3**. Lead variants associated with Covid-19 susceptibility (on 02.24.21)
616

Ancestry:Controls(:Sex)[a]	CHR:POS:NEA:EA	rsid	EAF	OR	±95CI	P (02.24.21)	Locus
ALL:Population	2:12594718:A:G	rs112938622	0.220	0.92	[0.90; 0.95]	4.95E-08	*MIR3681HG*
ALL:Population	3:45835417:G:A	rs73062389	0.058	1.21	[1.15; 1.27]	3.99E-13	*SLC6A20*
ALL:Population:F	3:45835417:G:A	rs73062389	0.058	1.22	[1.14; 1.31]	1.35E-08	*SLC6A20*
EUR:Population	3:45835417:G:A	rs73062389	0.060	1.22	[1.16; 1.29]	7.64E-14	*SLC6A20*
EUR:Population:F	3:45835417:G:A	rs73062389	0.060	1.23	[1.15; 1.32]	1.06E-08	*SLC6A20*
ALL:Tested	3:45839176:A:T	rs73062394	0.057	1.19	[1.12; 1.26]	1.99E-08	*SLC6A20;LZTFL1*
EUR:Tested	3:45839176:A:T	rs73062394	0.059	1.20	[1.13; 1.28]	1.85E-09	*SLC6A20;LZTFL1*
ALL:Population	9:136145425:C:A	rs9411378	0.219	1.10	[1.06; 1.13]	1.12E-09	*ABO*
ALL:Population:M	9:136145425:C:A	rs9411378	0.219	1.14	[1.09; 1.19]	2.00E-09	*ABO*
EUR:Population	9:136145425:C:A	rs9411378	0.222	1.10	[1.07; 1.14]	7.36E-10	*ABO*
EUR:Population:M	9:136145425:C:A	rs9411378	0.222	1.14	[1.09; 1.20]	2.05E-09	*ABO*
nEUR:Population	10:78250184:T:C	rs114026383	0.016	2.42	[1.78; 3.29]	1.82E-08	*LRMDA*
ALL:Tested:F	15:75602162:A:G	rs71401691	0.069	1.23	[1.14; 1.32]	4.72E-08	*GOLGA6D;COMMD4*
EUR:Population	20:651103:CG:C	rs749199237	0.350	1.08	[1.05; 1.11]	1.29E-08	*SCRT2*

617
618 [a] Indicate the ancestry by label, the control set, and, when it is the case, the corresponding sex-stratified analyses (F: Females,
619 M: Males)
620 CHR: Chromosome; POS: Position (hg19 genome build); NEA: Non Effect Allele; EA: Effect Allele; EAF: Effect Allele Frequency;
621 OR: Odd-ratio; ±95CI: 95% confidence interval [lower bound; upper bound]; P: P-value (from the last data release, analyzed on
622 02.24.21)

643 **Table 4**. Lead variants associated with Covid-19 hospitalization, severity, or death (on 02.24.21)
644

Phenotype	Ancestry:Controls(:Sex)[a]	CHR:POS:NEA:EA	rsid	EAF	OR	±95CI	P (02.24.21)	Locus
Hospitalization	EUR:Population	3:45843242:G:A	rs13071258	0.071	1.47	[1.29; 1.69]	3.18E-08	*SLC6A20;LZTFL1*
Hospitalization	EUR:Tested	3:45843242:G:A	rs13071258	0.071	1.49	[1.29; 1.71]	2.03E-08	*SLC6A20;LZTFL1*
Hospitalization	ALL:Population	3:45850783:T:A	rs72893671	0.081	1.43	[1.27; 1.61]	6.04E-09	*SLC6A20;LZTFL1*
Hospitalization	ALL:Tested	3:45850783:T:A	rs72893671	0.083	1.45	[1.29; 1.64]	1.99E-09	*SLC6A20;LZTFL1*
Severe	ALL:Population	3:45909644:C:A	rs13092887	0.075	1.72	[1.43; 2.07]	1.01E-08	*LZTFL1*
Severe	ALL:Tested	3:45909644:C:A	rs13092887	0.076	1.72	[1.43; 2.08]	1.04E-08	*LZTFL1*
Severe	EUR:Population	3:45909644:C:A	rs13092887	0.076	1.73	[1.43; 2.10]	2.38E-08	*LZTFL1*
Severe	EUR:Tested	3:45909644:C:A	rs13092887	0.076	1.73	[1.42; 2.09]	2.72E-08	*LZTFL1*
Hospitalization	ALL:Positive:M	6:34866730:G:C	rs112018241	0.015	3.10	[2.10; 4.60]	1.56E-08	*ANKS1A*
Hospitalization	ALL:Tested:M	6:35042053:C:T	rs112887370	0.015	2.89	[1.98; 4.21]	3.35E-08	*ANKS1A*
Hospitalization	EUR:Positive:M	6:35042053:C:T	rs112887370	0.015	3.30	[2.18; 5.00]	1.71E-08	*ANKS1A*
Hospitalization	EUR:Tested:M	6:35042053:C:T	rs112887370	0.014	3.16	[2.11; 4.76]	3.19E-08	*ANKS1A*
Hospitalization	EUR:Positive:F	12:7800075:A:ATTAT	rs370732090	0.857	0.61	[0.52; 0.73]	3.37E-08	*CD163;APOBEC1*
Severe	EUR:Population:F	19:6921713:G:GT	rs770180814	0.223	1.78	[1.45; 2.19]	4.51E-08	*ADGRE1*

645
646 [a] Indicate the ancestry by label, the control set, and, when it is the case, the corresponding sex-stratified analyses (F: Females,
647 M: Males)
648 CHR: Chromosome; POS: Position (hg19 genome build); NEA: Non Effect Allele; EA: Effect Allele; EAF: Effect Allele Frequency;
649 OR: Odd-ratio; ±95CI: ±95% Confidence interval [lower bound; upper bound]; P: P-value (from the last data release, analyzed on
650 02.24.21)

677 **Table 5.** Suggestive trends with p < 0.05 in Covid-19hgi meta-analyses
678

| CHR:POS:NEA:EA | rsid | EAF | UK Biobank GWAS | | | Covid-19hgi Meta-analysis | | | Locus |
			Phenotype:Ancestry: Controls(:Sex)[a]	OR.022421	P.022421	Meta-analysis	OR	P	
21:35293087:G:A	rs12482569	0.171	Hospitalization:ALL: Population	1.22	6.28E-06	B2_ALL	1.09	1.39E-04	*ATP5PO; LINC00649*
17:34415356:C:A	rs2011959	0.374	Severe:ALL:Positive:M	1.34	6.50E-06	A2_ALL	1.14	2.63E-04	*CCL3*
10:134354639:T:C	rs4880413	0.623	Hospitalization:ALL: Positive:M	1.25	7.05E-06	B2_ALL	1.05	0.018	*INPP5A*
1:63495201:T:C	rs79265284	0.022	Hospitalization:ALL: Positive:M	2.08	9.80E-06	B2_ALL	1.17	0.021	*LINC01739; LINC00466*
21:34156633:T:C	rs12627142	0.270	Susceptibility:EUR: Tested:M	1.11	5.92E-06	C2_EUR	1.03	0.024	*C21orf62-AS1*
8:138805432:G:A	rs6577840	0.899	Severe:ALL:Positive:M	1.74	1.10E-07	A2_ALL	1.12	0.025	*LOC101927915; LOC401478*
8:138803782:T:C	rs7835023	0.904	Severe:EUR:Positive:M	1.72	9.10E-07	A2_EUR	1.15	0.032	*LOC101927915; LOC401478*
10:134354639:T:C	rs4880413	0.624	Hospitalization:EUR: Positive:M	1.27	2.96E-06	B2_EUR	1.05	0.032	*INPP5A*
14:34041605:T:C	rs143195932	0.013	Hospitalization:EUR: Positive:M	3.41	6.48E-06	B2_EUR	1.29	0.032	*NPAS3*
10:37877569:T:C	rs4934590	0.293	Severe:EUR: Population:M	1.38	1.34E-06	A2_EUR	1.10	0.042	*LINC00993; MTRNR2L7*
5:17189240:G:A	rs188950364	0.019	Severe:ALL:Tested:M	3.21	3.57E-07	A2_ALL	1.22	0.042	*BASP1-AS1*
9:90051212:T:C	rs17052840	0.086	Severe:EUR: Population:F	2.05	5.72E-06	A2_EUR	1.12	0.043	*LINC02872; DAPK1*
21:34156633:T:C	rs12627142	0.270	Susceptibility:ALL: Tested:M	1.11	3.26E-06	C2_ALL	1.02	0.044	*C21orf62-AS1*
1:203193134:T:G	rs2486068	0.185	Severe:ALL: Population:M	1.42	4.01E-06	A2_ALL	1.09	0.046	*CHIT1*
15:101940428:G:A	rs1552946	0.732	Severe:EUR: Tested:F	0.64	5.64E-06	A2_EUR	0.92	0.048	*PCSK6*
22:28624425:T:C	rs28701638	0.160	Severe:EUR:Positive	0.73	9.63E-06	A2_EUR	0.92	0.048	*TTC28*
5:92032219:G:A	rs17082483	0.090	Severe:ALL:Positive:M	1.77	4.26E-07	A2_ALL	1.09	0.048	*ARRDC3-AS1; NR2F1-AS1*
4:27510227:A:T	rs4377577	0.164	Susceptibility:ALL: Population:F	1.10	8.86E-06	C2_ALL	1.03	0.048	*LINC02261; MIR4275*

679
680 [a] Indicate the phenotype, the ancestry, the control set, and, when it is the case, the corresponding sex-stratified analyses (F:
681 Females, M: Males)
682 CHR: Chromosome; POS: Position (hg19 genome build); NEA: Non Effect Allele; EA: Effect Allele; EAF: Effect Allele Frequency; P:
683 P-value
684